---
title: "BioStem Tech | 8-K: FY2026 Q2 Revenue: USD 7.899 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295715480.md"
datetime: "2026-08-12T22:07:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295715480.md)
  - [en](https://longbridge.com/en/news/295715480.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295715480.md)
generator: "portal-rs"
---

# BioStem Tech | 8-K: FY2026 Q2 Revenue: USD 7.899 M

Revenue: As of FY2026 Q2, the actual value is USD 7.899 M.

EPS: As of FY2026 Q2, the actual value is USD -0.52.

EBIT: As of FY2026 Q2, the actual value is USD -8.377 M.

#### Net Revenue

BioStem Technologies, Inc. reported net revenue of $7.9 million for the second quarter of 2026, representing a 29% sequential growth from $6.1 million in the first quarter of 2026. This compares to $11.0 million in the second quarter of 2025. Revenue for the second quarter was primarily driven by Neox® and Clarix® product sales.

#### Segment Revenue

Hospital revenue reached $6.7 million in the second quarter of 2026, an increase from $5.7 million in the first quarter of 2026. Physician office revenue was $1.1 million in the second quarter, up from $0.8 million in the first quarter of 2026.

#### Gross Profit and Gross Margin

Gross profit for the second quarter of 2026 was $4.8 million, representing a gross margin of 61%. This is an increase from $3.8 million in gross profit with a 61% gross margin in the first quarter of 2026. In the second quarter of 2025, gross profit was $10.3 million with a gross margin of 94%. The sequential increase in gross profit was due to higher revenue, while the gross margin remained flat sequentially.

#### Operating Expenses

Total operating expenses were $13.2 million in the second quarter of 2026, compared to $12.6 million in the first quarter of 2026 and $10.2 million in the second quarter of 2025. The sequential increase was mainly due to the expanding commercial team and infrastructure, partially offset by lower clinical trial and administrative spending.

#### GAAP Net Loss

BioStem Technologies, Inc. reported a GAAP net loss of - $9.0 million, or - $0.52 per share, for the second quarter of 2026. This contrasts with a net income of $10,613, or $0.00 per share, in the second quarter of 2025.

#### Adjusted EBITDA Loss

Adjusted EBITDA loss was - $4.6 million for the second quarter of 2026, compared to an Adjusted EBITDA of $2.5 million in the second quarter of 2025.

#### Cash and Cash Equivalents

As of June 30, 2026, cash and cash equivalents totaled $7.0 million. This is a decrease from $13.7 million at the end of the first quarter of 2026.

#### Cash Flow from Operations

Cash used in operations during the second quarter of 2026 was $5.5 million.

#### Unique Financial Events

During the second quarter, BioStem Technologies, Inc. closed a $2.5 million private financing. The company also resolved $5.3 million in outstanding debt through a $3.5 million cash payment and the issuance of a $1.0 million promissory note.

#### 2026 Financial Outlook

BioStem Technologies, Inc. has raised its full-year 2026 revenue guidance to a range of $26 million to $29 million. This represents an increase from its prior guidance of $25 million to $29 million.

### Related Stocks

- [BSEM.US](https://longbridge.com/en/quote/BSEM.US.md)

## Related News & Research

- [BioStem Q2 FY26 GAAP net loss widens to $9 million; revenue rises 29% to $7.9 million vs Q1](https://longbridge.com/en/news/295703785.md)
- [BioStem Technologies Reports Q2 2026: Revenue $7.9M, Gross Profit $4.8M, Adjusted EBITDA Loss $4.6M](https://longbridge.com/en/news/295713318.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**